|
KMID : 0869620130300010043
|
|
Journal of Korean Society of Hospital Pharmacists
2013 Volume.30 No. 1 p.43 ~ p.51
|
|
|
Risk of Bleeding and Effect of Stroke Prevention Between Warfarin Single Therapy and Warfarin-Aspirin Combination Therapy in Patients with Atrial Fibrillation
|
|
Park Ji-Eun
Lee Jung-Eun
Ko Jong-Hee
Ahn Ji-Hyune
Son Eun-Sun
Kim Sung-Eun
Seok Hyun-Joo
|
|
|
Abstract
|
|
|
Atrial fibrillation (AF), the most common sustained arrhythmia, confers an independent
risk factor for stoke. If the disease is not treated, stroke risk will increase more than five
times, and about one in three people will experience a stroke during their life time. Therefore, AF eeds active management, and anticoagulation therapy is effective in the prevention of stroke.
Warfarin and aspirin, the medicines for the prevention and treatment of thromboembolism, are ffective in the prevention of stroke in AF. Medication is determined by stroke risk, generally lassified by CHADS2 score. Warfarin is recommended primarily for high-risk patients, and spirin is recommended for low-risk patients and those unable to take warfarin. Despite the ombined warfarin-aspirin therapy is not recommended in general, cmplementary effects are expected due to different mechanisms of the drug. However, some cases have been reported that the combination of these medications just administered to increase bleeding risks and did not represent a remarkable therapeutic effect.
Therefore, this study is in 2011, Jan. 1 to Oct. 31 in outpatients with AF who underwent the
anticoagulation therapy, and patients were classified according to medication uses. This study was analyzed cardiovascular diseases, medical treatments, and hematologic data. In addition, this study retrospectively analyze the status of anticoagulation therapy in patients with AF. The warfarin group and warfarin+aspirin group were 54 and 51 patients and average duration of drug administration were 4.7 and 3.6 months, respectively. Bleeding events occurred in 5 and 6 patients in warfarin group and warfarin+aspirn group, respectively. Retrospective analysis of the two drugs showed no significant differences between the bleeding risk and stroke prevention, additional research is needed for the clinical evaluation of the combination therapy of warfarin and aspirin.
|
|
|
KEYWORD
|
|
|
Atrial fibrillation, Warfarin, Aspirin, Combination therapy, Bleeding risk, Stroke
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|